CN107849104B - Tau结合抗体 - Google Patents

Tau结合抗体 Download PDF

Info

Publication number
CN107849104B
CN107849104B CN201680039795.4A CN201680039795A CN107849104B CN 107849104 B CN107849104 B CN 107849104B CN 201680039795 A CN201680039795 A CN 201680039795A CN 107849104 B CN107849104 B CN 107849104B
Authority
CN
China
Prior art keywords
tau
ser
gly
thr
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680039795.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849104A (zh
Inventor
D·E·O·奈特
T·S·贝克
D·J·麦克米兰
R·A·格里芬
G·麦雷特-科罗
P·唐尼
J-P·库拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107849104(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CN107849104A publication Critical patent/CN107849104A/zh
Application granted granted Critical
Publication of CN107849104B publication Critical patent/CN107849104B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
CN201680039795.4A 2015-07-06 2016-07-05 Tau结合抗体 Active CN107849104B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06
EP15175522.0 2015-07-06
PCT/EP2016/065813 WO2017005734A1 (en) 2015-07-06 2016-07-05 Tau-binding antibodies

Publications (2)

Publication Number Publication Date
CN107849104A CN107849104A (zh) 2018-03-27
CN107849104B true CN107849104B (zh) 2021-08-27

Family

ID=53524640

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680039795.4A Active CN107849104B (zh) 2015-07-06 2016-07-05 Tau结合抗体

Country Status (25)

Country Link
US (4) US10287343B2 (enExample)
EP (1) EP3319983A1 (enExample)
JP (3) JP6630426B2 (enExample)
KR (2) KR102770650B1 (enExample)
CN (1) CN107849104B (enExample)
AR (1) AR105267A1 (enExample)
AU (1) AU2016289755C1 (enExample)
CA (1) CA2991451A1 (enExample)
CL (1) CL2018000043A1 (enExample)
CO (1) CO2017012971A2 (enExample)
EA (1) EA037092B1 (enExample)
EC (1) ECSP18000887A (enExample)
IL (1) IL256685B (enExample)
MA (2) MA41670A1 (enExample)
MX (1) MX2017015817A (enExample)
MY (1) MY193677A (enExample)
PE (1) PE20180481A1 (enExample)
PH (1) PH12017502207B1 (enExample)
SG (1) SG10202010735PA (enExample)
TN (1) TN2017000539A1 (enExample)
TW (1) TWI745295B (enExample)
UA (1) UA124616C2 (enExample)
UY (1) UY36773A (enExample)
WO (1) WO2017005734A1 (enExample)
ZA (1) ZA201800027B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
CA2991451A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
WO2021030615A1 (en) * 2019-08-13 2021-02-18 Washington University Methods to detect mtbr tau isoforms and use thereof
JP7399305B2 (ja) 2020-02-12 2023-12-15 イーライ リリー アンド カンパニー 抗体または抗原結合フラグメントの結晶化
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
PE20251700A1 (es) * 2022-11-14 2025-07-02 Washington University St Louis Metodos para detectar mtbr-tau en el lcr y sus usos
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025171285A1 (en) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Tau proteomimetics
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1492879A (zh) * 2001-02-02 2004-04-28 �ѧ�о��ͷ�չ�ɷ����޹� tau蛋白
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
CN101307108A (zh) * 2008-06-25 2008-11-19 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
WO2014008404A1 (en) * 2012-07-03 2014-01-09 Washington University Antibodies to tau
WO2014028777A2 (en) * 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
CN104024274A (zh) * 2011-12-20 2014-09-03 詹森生物科技公司 抗PHF-tau抗体及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
RU2011125367A (ru) 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты лептина и аналогов лептина и их применение
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
US20120277158A1 (en) 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
DK2625198T3 (en) 2010-10-07 2015-09-28 Ac Immune Sa Antibodies that recognize the phosphorylated tau
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SMT201800109T1 (it) 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
SG11201401649VA (en) 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
CA2991451A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1492879A (zh) * 2001-02-02 2004-04-28 �ѧ�о��ͷ�չ�ɷ����޹� tau蛋白
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
CN101307108A (zh) * 2008-06-25 2008-11-19 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
CN104024274A (zh) * 2011-12-20 2014-09-03 詹森生物科技公司 抗PHF-tau抗体及其用途
WO2014008404A1 (en) * 2012-07-03 2014-01-09 Washington University Antibodies to tau
WO2014028777A2 (en) * 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anti-tau antibody reduces insoluble tau and decreases brain atrophy;Kiran Yanamandra等;《ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY》;20150123;第2卷(第3期);第278-288页 *
Tau protein isoforms,phosphorylation and role in neurodegengrativedisorders;Buee L等;《BRAIN RESEARCH REVIEWS》;20000801;第33卷(第1期);第95-130页 *

Also Published As

Publication number Publication date
JP6630426B2 (ja) 2020-01-15
AU2016289755B2 (en) 2020-12-03
IL256685B (en) 2022-02-01
HK1246804A1 (zh) 2018-09-14
MA42377A (fr) 2018-05-16
NZ738058A (en) 2021-07-30
JP2020055849A (ja) 2020-04-09
IL256685A (en) 2018-03-29
ZA201800027B (en) 2019-06-26
MX2017015817A (es) 2018-04-10
KR20180025962A (ko) 2018-03-09
TN2017000539A1 (en) 2019-04-12
CL2018000043A1 (es) 2018-05-18
JP2018524001A (ja) 2018-08-30
AU2016289755C1 (en) 2021-08-19
AU2016289755A1 (en) 2018-01-04
US11732034B2 (en) 2023-08-22
KR102770650B1 (ko) 2025-02-19
KR20250027278A (ko) 2025-02-25
US20230416350A1 (en) 2023-12-28
EA201890172A1 (ru) 2018-10-31
MA41670A1 (fr) 2018-05-31
PH12017502207B1 (en) 2022-08-10
SG10202010735PA (en) 2020-11-27
CO2017012971A2 (es) 2018-03-09
TW201713689A (zh) 2017-04-16
UY36773A (es) 2017-01-31
CN107849104A (zh) 2018-03-27
BR112017028102A2 (en) 2018-09-04
ECSP18000887A (es) 2018-03-31
US10287343B2 (en) 2019-05-14
US20180201666A1 (en) 2018-07-19
JP7413448B2 (ja) 2024-01-15
US20210115121A1 (en) 2021-04-22
US20190284267A1 (en) 2019-09-19
AR105267A1 (es) 2017-09-20
JP2022141689A (ja) 2022-09-29
UA124616C2 (uk) 2021-10-20
EA037092B1 (ru) 2021-02-04
WO2017005734A1 (en) 2017-01-12
JP7100008B2 (ja) 2022-07-12
TWI745295B (zh) 2021-11-11
EP3319983A1 (en) 2018-05-16
CA2991451A1 (en) 2017-01-12
MY193677A (en) 2022-10-25
PH12017502207A1 (en) 2018-06-11
PE20180481A1 (es) 2018-03-07
US10889640B2 (en) 2021-01-12

Similar Documents

Publication Publication Date Title
CN107849104B (zh) Tau结合抗体
KR100442019B1 (ko) 사구체신염 및 다른 염증 질환의 치료방법 및 치료용 조성물
EP2788379B1 (en) Pdgf receptor beta binding polypeptides
TWI748954B (zh) Ｔａｕ結合抗體
TWI545132B (zh) 人類化抗－ＴＡＵ（ｐＳ４２２）抗體及使用方法
KR102150616B1 (ko) c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
KR20150062698A (ko) 항 c-Met/항 Ang2 이중 특이 항체
KR102390359B1 (ko) 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
KR102277813B1 (ko) 항 c-Met 항체의 항-이디오타입 항체
TW202014209A (zh) 用於消融造血幹細胞之抗體藥物軛合物
HK1246804B (zh) Tau结合抗体
KR101985299B1 (ko) 항-c-Met/항-Nrp1 이중 특이 항체
KR20150088433A (ko) c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
CN105925610B (zh) 昆虫杆状病毒表达载体、构建方法及其应用
CN116135882B (zh) 一株羊驼源纳米抗体m112及其应用
CN116135880B (zh) 一株羊驼源纳米抗体s140及其应用
KR20150133576A (ko) 화학적 개질된 표적화 단백질 및 그의 이용
KR102291465B1 (ko) c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
KR20160024639A (ko) c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
HK1202882B (en) Pdgf receptor beta binding polypeptides
HK1244676B (zh) 碳矽烷树枝状体及用於药物递送系统的使用该树枝状体获得的可聚集载体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246804

Country of ref document: HK

CB02 Change of applicant information

Address after: Brussels

Applicant after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Applicant before: UCB BIOPHARMA SPRL

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant